"Exploring Health Innovation Future" – China's First Post-Diagnosis Disease Management and Digital Therapeutics Entrepreneurship & Innovation Competition Opens for Applications!
With the advancement of national tiered diagnosis and treatment, differentiated management of acute and chronic conditions, and initiatives to improve medical services, patient management issues for those requiring long-term follow-up and treatment guidance—such as individuals with common diseases, chronic conditions, and tumors—have become increasingly prominent. Post-consultation management is growing in critical importance and has become a top priority in healthcare delivery.
Meanwhile, amid the outbreak of the COVID-19 pandemic in 2020, the advantages of digital therapeutics—remote, portable, and personalized interventions—were significantly amplified. Countries around the world have successively introduced policies to encourage industry development, positioning digital therapeutics at a pivotal point of rapid growth and poised for takeoff.
To seize current development opportunities, enhance public awareness of post-diagnosis disease management and digital therapeutics, identify a cohort of high-quality innovative startups in disease management and digital therapeutics, accelerate the application of digital therapeutics in clinical settings, and promote the development of China’s disease management and digital therapeutics industry,Probe Capital and Jianhai Technology Jointly Launch “Probing the Future of Health—China’s First Post-Consultation Disease Management and Digital Therapeutics Innovation and Entrepreneurship Competition”!
This is not just a competition, but also:
The competition has been meticulously designed for participating enterprisesA Set of Training Courses, helping enterprises restructure their business models, identify core competitive advantages, and support sustainable growth.
The competition provides winning projects withMillion-Dollar Prize, while the competition is backed by numerous partner investment institutions and healthcare industry giants, significantly increasing projects’ exposure in the capital market and enhancing fundraising efficiency.
The competition will launch post-diagnosis disease management and digital therapeutics in major cities.National Tour Seminar, inviting renowned medical experts and department directors, investment institutions, and digital health projects to engage in a broad discussion, with the aim of enhancing public awareness of digital therapeutics and promoting their clinical translation.
Leveraging Jianhai Technology,Winning enterprises are expected to join the Jianhai ecosystem., reducing the cost for startups to gain hospital access, empowering enterprises in clinical applications, and enhancing the clinical efficiency of digital therapeutics.
Here, you will encounter manyEntrepreneurial Companions, perhaps sparking new ideas.
We will also invite renowned investors and medical experts to serve as judges for the competition, providing participating companies with the most professional feedback and guidance.
Organizer
Hangzhou Jianhai Science and Technology Co., Ltd. (hereinafter referred to as “Jianhai”Technology") InnovationFounded in 2015, we are a high-tech enterprise leveraging artificial intelligence to build and operate post-diagnosis disease management services. Guided by the philosophy of “Making Care a Potent Remedy,” we are committed to advancing the development of post-diagnosis disease management systems, thereby providing patients with a better quality of life and safer medical services.
For many years, Jianhai Technology has been deeply engaged in the post-diagnosis healthcare sector. To address post-diagnosis disease management, it has launched three major series under the “C.S.D” framework and established the foundational infrastructure for a hospital-based digital therapeutics platform. These include the “C Series – Co-built Post-Diagnosis Disease Management Services,” the “S Series – Smart Patient Service Platform,” and the “D Series – Digital Therapeutics Platform and Research.” The company drives commercial operations through services, leverages data as its core asset, enhances industry efficiency with AI, and builds a digital therapeutics ecosystem grounded in data security. By implementing its “Three Horizontal, One Vertical” strategy, Jianhai Technology ultimately aims to realize a new model for the development and service operation of post-diagnosis disease management.
Meanwhile, leveraging AI to overcome key bottlenecks in post-diagnosis disease management services, reduce disease management costs, and improve the quality of disease management, thereby truly realizing human-centric, holistic, and end-to-end health management.
Probe Capital is a boutique investment bank specializing in healthcare and life sciences. Founded in 2017, its founding team hails from leading private equity firms, financial advisory institutions, management consulting companies, and vertical healthcare media outlets. Since its establishment, the firm has consistently completed double-digit private financing and M&A transactions annually, with cumulative transaction values approaching RMB 10 billion. The Probe Capital team also possesses extensive expertise in providing value-added services to portfolio companies. In 2020, Probe New Healthcare Fund was established and has since invested in multiple industry-leading companies.
AstraZeneca entered the Chinese market in 1993. Headquartered in Shanghai, it has established regional headquarters in Beijing, Guangzhou, Wuxi, Hangzhou, and Chengdu. The company has invested in manufacturing bases in Wuxi and Taizhou, Jiangsu Province, and set up its China logistics center in Wuxi. AstraZeneca employs over 20,000 people across China. In China, AstraZeneca’s business focuses primarily on therapeutic areas with the most urgent patient needs, including respiratory, cardiovascular, metabolic, oncology, gastrointestinal, and renal diseases. By collaborating with cross-sector partners from government, industry, academia, research institutions, and healthcare, AstraZeneca has jointly established the Hangzhou Digital Healthcare Innovation Center. This initiative aims to provide integrated solutions covering the entire disease journey for major conditions in China by building an open, innovative health ecosystem centered on patients.
In 2019, AstraZeneca China announced the launch of the “International Life Science Innovation Campus (iCampus),” a government-enterprise collaboration project designed to provide a one-stop incubation and acceleration platform for high-quality innovative medical projects from both domestic and international markets. To date, more than 40 innovative enterprises from home and abroad have settled in the campus. As a key hub within this network, the Hangzhou International Life Science Innovation Campus will empower the development of the life sciences industry with a focus on digital health, facilitate enhanced innovation synergy across the Yangtze River Delta region, and bolster the global influence of the regional smart healthcare innovation cluster.
Royal Philips is a leading health technology company dedicated to supporting healthcare systems in achieving the Quadruple Aim—improving population health, enhancing the work life of care providers, improving patient experience, and lowering the cost of care—across the entire “health continuum,” from healthy living and disease prevention to diagnosis, treatment, and home care. Leveraging advanced technologies, extensive clinical expertise, and deep consumer insights, Philips strives to realize this mission. The company’s vision is to enable a healthier and more sustainable world through meaningful innovation, aiming to improve the lives of 2.5 billion people annually by 2030.
Headquartered in the Netherlands, Philips reported sales of €19.5 billion in 2020, employs approximately 82,000 people worldwide, and maintains sales and service operations in more than 100 countries. The company is currently a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, and consumer health and home care.position.
Tasly Capital was founded in 2007. Its business scope covers equity investment, industrial M&A, financial leasing, asset management, international investment, and commercial factoring. The company employs over 120 professionals and maintains offices in Tianjin, Beijing, Shanghai, Chongqing, and Hong Kong. After more than a decade of development, it has established a specialized fund portfolio comprising VC funds, PE funds, M&A funds, cooperative funds, and special-purpose funds. The total assets under management amount to RMB 12.5 billion, including seven RMB-denominated funds and three USD-denominated funds, with investments in over 90 companies.
Tasly Capital will continue to closely monitor trends in the macroeconomic and industry landscapes, swiftly grasp the direction of technological变革, meticulously identify investment tracks, and explore differentiated pathways to success. It will remain committed to its 4D (Diagnostics, Drugs, Devices, and Digital Health) investment principles, focusing its investments on the four core therapeutic areas of cardiovascular and cerebrovascular diseases, oncology, digestive and metabolic disorders, and respiratory conditions, while continuing to pay close attention to major technological breakthroughs and product innovations in other fields.
Sequoia Capital has always been committed to helping entrepreneurs build enduring, great companies, bringing abundant global resources and valuable historical experience to its portfolio companies. Over the past 49 years, Sequoia Capital has invested in numerous innovative enterprises and leaders shaping industry trends.
Sequoia Capital China, as “entrepreneurs behind entrepreneurs,” focuses on investment opportunities in three sectors: TMT, healthcare, and consumer goods/modern services. Over the past 16 years, Sequoia Capital China has invested in nearly 600 companies characterized by distinct technological features, innovative business models, and high growth potential.
Fidelity International’s private markets investment arm, F-Prime Capital (formerly known as Fidelity Growth Partners), is a global self-managed investment institution backed by the Fidelity Group. Leveraging its unique capital structure, F-Prime Capital flexibly deploys capital to support innovative companies in disrupting or leading their respective markets, empowering entrepreneurs to realize their ambitions. Currently, together with affiliated funds under the Fidelity Group, F-Prime Capital ranks among the top ten venture capital firms globally. Our global ecosystem continuously provides portfolio companies with access to an extensive talent pool and deep local expertise, facilitating their business growth. With over 25 years of venture capital experience in China, F-Prime Capital has invested in more than 110 companies in the healthcare and technology innovation sectors. Over the past decade, we have invested nearly $6 billion in startups worldwide.
Sherpa Capital is a specialized fund focused on early-stage healthcare investments. Adhering to an investment philosophy centered on building industry ecosystems, it constructs its portfolio by targeting rigid, unmet medical needs, leveraging deep expertise in the treatment of major diseases, and strategically positioning itself across the industry’s vertical depth as well as its upstream and downstream sectors.
By actively sharing operational expertise and forward-looking, full-industry-chain insights with portfolio companies, the team proactively fosters internal and external synergy, helping enterprises achieve rapid growth in both business performance and valuation, while securing leading positions in their respective niche markets. The firm has invested in industry-leading enterprises across specialized sectors such as healthcare services, pharmaceuticals, gene technology, and medical devices, thereby cultivating comprehensive resource advantages in deal sourcing, post-investment value-added services, and exit strategies. From 2011 to 2021, spanning four fund vintages and over 100 healthcare investments, the team has had the privilege of partnering with numerous outstanding entrepreneurs, growing together along the journey.
Source Code Capital was founded in the spring of 2014, dedicated to discovering and empowering leading enterprises in the wave of the information revolution. It currently manages $2.5 billion and RMB 8.8 billion.
Source Code Capital adheres to first-principles thinking and in-depth research to drive its investment decisions. Within its “Three Horizontal, Nine Vertical” investment framework, the firm has gradually built a portfolio of over 200 companies, propelled by three core strategic themes: “Internet+,” “Intelligence+,” and “Global+.” These investments span major sectors including media and content, consumer services, industrial enterprises, finance, retail, automotive and real estate, and education and healthcare.
Member companies (partial list) include: ByteDance, Meituan (3690.HK), Ke Holdings (NYSE:BEKE); Li Auto (NASDAQ:LI), Niu Technologies (NASDAQ:NIU), RELX (NYSE:RLX), Narwal, Ziroom, Julihouse, Huizhaofang, Pagoda, Mogu Inc. (NYSE:MOGU), Xinchao Media, Walnut Coding, Weimai, Huishoubao, Linji, Qinzhu, Chayan Yuese, Wang Baobao, Blokees; Yijiupi, Yimidida, Yaodianyun, Baibu, Easypoint Cloud, Zhongneng United, Pudu Robotics, Chuxin, Yunquna, Ruigu, Casstime, Che300; Qudian (NYSE:QD), Asset 360, Woniu Insurance, Ci Finance, Abbots; KrazyBee, Zenjoy, BLUE, OPay, etc.
As a professional investment institution with the most extensive global industrial resources, Cathay Capital shares knowledge and business opportunities through its unique global ecosystem.
Founded in 2006, Cathay Capital currently manages over USD 4 billion in assets and has invested in more than 190 companies across four continents. The firm primarily focuses on highly innovative enterprises with strong growth potential in sectors including consumer goods, TMT (Technology, Media, and Telecom), healthcare, automotive and mobility, energy, fintech, and advanced manufacturing. It has identified and invested in dozens of high-quality companies such as Suofeiya Home Collection, Zbom Home, Meinian Onehealth, Moncler, Botian Environment, AiHuiShou, JD Logistics, Deerma, and Zongteng Network; star unicorn projects like Momenta, Pinduoduo, Chime, Genki Forest, Drivy, Glovo, and Sidecar; as well as prominent healthcare ventures including Panview Medical, Paizhen Biotechnology, Yiyong Technology, Ruisun Biotech, Medimaging Intelligence, Kojin Therapeutics, and Fapon Biotech, supporting their growth into industry leaders.
Over its 15-year history, Cathay Innovation has enjoyed continuous support from a diverse global investor base, including sovereign wealth funds from China, Europe, Southeast Asia, and the Middle East; Fortune Global 500 companies; established family offices with long-standing histories; and mainstream financial institutions such as banks and insurance companies. Nearly half of the companies listed on France’s CAC 40 index are ongoing investors in Cathay Innovation.
Cathay Capital has offices in Paris, Shanghai, Beijing, New York, San Francisco, Munich, Shenzhen, Tel Aviv, and Singapore. Its global team of over 120 investment professionals leverages multicultural perspectives and a global vision, combining unique business models, value-added strategies, and deep-rooted local networks and resources to serve investors and portfolio companies by uncoveringAnd accompany XinyiThe growth of world-class enterprises.
LYFE Capital is a healthcare investment firm established in 2015, with assets under management totaling $1.3 billion. We are dedicated to investing in companies in the Chinese and U.S. markets that boast exceptional management teams and compelling visions. Our investment focus spans innovative drugs, biotechnology, medical devices, and diagnostics, covering all stages from innovation and early growth to pre-IPO.
LYFE envisions becoming a premier biomedical investment fund rooted in China with a global perspective. By leveraging the synergy of professional investment teams in both China and the United States, LYFE provides cross-border value-added services to its portfolio companies, including strategic partnerships for innovative products, domestic and overseas M&A advisory, and strategic and operational support. These efforts empower companies to grow and unlock their full potential in a rapidly evolving market, thereby delivering superior services and products.
Sanzheng Health Investment is a private equity fund dedicated to the healthcare industry. We focus on unmet clinical needs, investing in innovative healthcare technologies to drive their clinical translation and industrialization, thereby saving more lives while improving patients’ quality of life. Leveraging our deep resources in clinical practice, industry, and policy, we collaborate with partners to build great health technology enterprises.
Yuan Yi Capital was established in 2016 as an early-stage venture capital fund focused on the digital healthcare technology sector. Currently, Yuan Yi manages multiple RMB and USD-denominated funds.
Yuan Yi Capital focuses on investing in the structural opportunities brought by digital technologies to China’s healthcare industry. To date, Yuan Yi has invested in over 40 companies that are transforming patient access, operational efficiency, and payment mechanisms within China’s healthcare sector. Representative portfolio companies include Shukun Technology, Medbanks, Xunshi Technology, Daoke Technology, Beden Medical, Lainuo Medical, and Basecare.
Starting a business is arduous, especially in China. We are inspired by the passion and energy of our entrepreneurial partners, and Yuan Yi is committed to continuously providing them with resources and support to help them successfully navigate the many challenges inherent in building a startup. At Yuan Yi, we stand ready to join hands with entrepreneurs, embodying our motto: “Together we go far; with perseverance, we achieve success.”
HaibangFenghuaEstablished in 2011, the firm adheres to a core strategy centered on “technology and talent,” pioneering investment and services for high-caliber professionals within the industry. The fund primarily focuses on three major hubs of scientific and technological innovation: life and health, the digital economy, and new materials, with a key emphasis on early- to mid-stage projects founded by high-level talents. Currently, the fund’s total size amounts to nearly RMB 4 billion. It has invested in approximately 90 companies, among which 13 have completed initial public offerings (IPOs), 5 have gone public through mergers and restructurings, and 15 have been recognized as “unicorn” enterprises. Additionally, more than 10 portfolio companies are actively preparing for IPOs.
Changling Capital, established in 2016, is a new generation of theme-driven venture capital fund. The founding partners of Changling come from NEA (New Enterprise Associates), one of the largest venture capital funds in the United States, and were responsible for NEA's investments in China from 2005 to 2015. In the field of healthcare and aging, Changling Capital is committed to investing in technology-driven business model innovations, making longevity a gift of life for everyone in China's rapidly aging society. Changling Capital has offices in Shanghai and Beijing, with total assets under management reaching RMB 6 billion. Its investors include endowments and foundations from globally renowned universities and hospitals, pension funds, top-tier fund-of-funds, and other first-class investment institutions.
Shengshi Consulting is a consulting firm dedicated to the healthcare industry. Its multidisciplinary team provides proactive strategic, industrial, financing, and legal advisory services to healthcare innovation enterprises, with the aim of continuously helping clients uncover and enhance their commercial and capital value. Leveraging deep insights into the healthcare industry and capital markets, Shengshi is able to offer more direct support for companies’ business operations and capitalization efforts. To date, the team has served over 100 healthcare companies and provided advisory services to the founding teams of more than 300 healthcare enterprises.